Assuntos
Vacinas contra Influenza , Influenza Humana , Vacinação , Humanos , Vacinas contra Influenza/administração & dosagem , Influenza Humana/prevenção & controle , Vacinação/normas , Idoso , Pessoa de Meia-Idade , Feminino , Masculino , Adulto , Guias de Prática Clínica como Assunto , Espanha , Fatores de Risco , Adolescente , Adulto Jovem , Idoso de 80 Anos ou maisRESUMO
Pertussis is a highly contagious, vaccine-preventable respiratory tract infection, with high morbidity and mortality and a particularly severe effect on newborns and infants under 2 months. The first pertussis vaccines were introduced in the 1940s. Since 1980, however, the incidence of cases has risen despite the extensive vaccination programmes and antibiotic adjuvant treatments available. Transition from the use of whole-cell vaccines to acellular vaccines and the antigenic modifications of Bordetella pertussis have contributed, among other factors, to a reduction in vaccine-acquired immunity and reemergence of the disease. Today, there are still unmet needs not covered by conventional prevention measures and existing antibiotic treatments. This review aims to update the available data, and to discuss which vaccine strategies might contribute to better disease control and prevention.